Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration
- Sponsor
- Saglik Bilimleri Universitesi
- Study ID
- NCT07235527
- Status
- Completed
Conditions
- Age Related Macular Degeneration
- Anti Vascular Endothelial Growth Factor
- Exudative Age-Related Macular Degeneration
Eligibility Criteria
- Sex
- ALL
- Age
- 45 Years - 90 Years
- Healthy Volunteers
- Not accepted
Interventions
- Aflibercept biosimilar (MY-1701P) — DRUGPatients receiving the aflibercept biosimilar MY-1701P (marketed as Yesafili®) as part of routine clinical care.
Study Details
In this study, patients receiving Eylea treatment will be treated with Yesafili, a biosimilar molecule, and routine examination results will be noted.
Key Dates
- First listed
- Nov 19, 2025
- Start date
- Nov 20, 2025
- Status verified
- Aug 2026
- Primary completion
- Aug 20, 2026
- Completion
- Aug 30, 2026
Study Design
- Enrollment
- 54 participants (actual)
Arms
- Arm: patients treated with Yesafiliaflibercept biosimilar used
Primary Outcome Measure
Change in Best-Corrected Visual Acuity (BCVA) and Central Macular Thickness After MY-1701P Injection [ Time Frame: Baseline to Month 6 ]
Related Studies
- Strategies for Improving Linkage-to-Care After Eye Disease ScreeningRecruiting · University of California, San Francisco · San Francisco, California
- Phase 1 Study of C.001 in Retinal DegenerationPHASE1 · Recruiting · Cellio Therapeutics Inc · Beverly Hills, California